Pentosan Polysulfate
A semi-synthetic polysaccharide with FDA approval for interstitial cystitis, also studied for joint and cartilage health.
What is Pentosan Polysulfate?
Pentosan Polysulfate (PPS) is a semi-synthetic heparin-like compound derived from beechwood. It is FDA-approved (as Elmiron) for the treatment of interstitial cystitis (painful bladder syndrome). It is also a veterinary drug: Cartrophen Vet for canine osteoarthritis is registered in Australia, New Zealand, Canada, the UK, and much of Europe, and in the US the FDA approved Zycosan, an injectable pentosan polysulfate for osteoarthritis in horses, in December 2022. It is discussed in the peptide space for its potential joint and cartilage health benefits.
What Pentosan Polysulfate Is Investigated For
Pentosan Polysulfate is a semi-synthetic heparin-like polysaccharide (not technically a peptide) with FDA approval as Elmiron for interstitial cystitis, veterinary approval as Cartrophen for canine osteoarthritis, and off-label use for human joint and cartilage support with broader anti-inflammatory framing. The strongest evidence is for interstitial cystitis — FDA approval since 1996 and placebo-controlled trials pooled in meta-analyses showing a modest benefit, roughly one extra responder for pain per seven people treated — making it the only oral therapy specifically indicated for IC. The evidence is not uniform: the largest modern placebo-controlled trial (368 patients, 24 weeks) found no difference from placebo, and a 2020 Cochrane network meta-analysis found no evidence that it improved cure or improvement rates. Joint applications have weaker human data and lean heavily on veterinary evidence. In September 2026 the first large Phase 3 trial of injectable PPS for knee osteoarthritis — Paradigm Biopharmaceuticals' PARA_OA_012, which the company put at 538 participants against the 466 still estimated on ClinicalTrials.gov — met its pre-specified futility criterion at interim analysis, with the company attributing part of the result to a significant amount of missing data. The most consequential modern caveat is a unique pigmentary maculopathy associated with long-term oral use, characterized in the literature after 2018, with a 21-year FAERS pharmacovigilance analysis putting the median time-to-onset around 4.7 years, and a separate four-year prospective study showing that the retinal changes keep progressing after the drug is stopped — a shift that reframed the risk-benefit conversation and, in June 2020, put a retinal-pigmentary-changes warning on the label. Bleeding risk from heparin-like anticoagulant activity — and, per a 2026 laboratory study showing PPS engages platelet factor 4 comparably to heparin, a theoretical thrombocytopenia risk that is sharpest for injected routes — is an additional consideration, particularly in combination with anticoagulants or antiplatelet drugs. Strong for IC with real long-term safety flags; weaker case for off-label joint use.
History & Discovery
Pentosan polysulfate sodium (PPS) is a semi-synthetic, heparin-like polysaccharide produced by sulfating xylan extracted from beechwood. It was used in Europe as an antithrombotic agent before its definitive medical role emerged through urology rather than hematology. In 1996, the US FDA approved PPS as Elmiron for the relief of bladder pain or discomfort associated with interstitial cystitis (IC) — making it the only oral therapy specifically indicated for IC and a fixture of urology practice for the next two decades. PPS is also marketed under the name Cartrophen and analogous brands as a veterinary therapy for canine osteoarthritis, where its use is more clinically established than the human off-label joint applications discussed in the peptide and longevity space. PPS is not technically a peptide — it is a polysulfated polysaccharide — but it is frequently grouped into peptide and tissue-repair discussions because of overlapping use cases (joint, cartilage, soft tissue) and a shared mechanistic vocabulary around glycosaminoglycan biology. The most consequential development in PPS's modern history is the post-2018 emergence of literature describing a unique pigmentary maculopathy in long-term users — first characterized by Pearce and colleagues at Emory and subsequently confirmed across multiple ophthalmology cohorts. The FDA approved a retinal warning in June 2020, and litigation followed: the federal multidistrict litigation over Elmiron in the District of New Jersey has drawn 1,988 cases, 286 of them still pending as of 1 September 2026; the current safety conversation around PPS is dominated by this maculopathy issue rather than by its older anticoagulant or hematologic profile. Since the 2010s, PPS has had a second life as an injectable anti-inflammatory. A small open-label study in four people with mucopolysaccharidosis type I reported lower urinary glycosaminoglycan fragments at 73 weeks and reduced pain-interference, pain-behavior and fatigue scores in all four, and a Phase 2a trial in Ross River virus arthritis was positive. Paradigm Biopharmaceuticals then ran a 602-participant adaptive study and the Phase 3 PARA_OA_012 trial in knee osteoarthritis, which the company described as enrolling 538 while the registry record still gives an estimated 466 and, as of its September 2026 update, carries neither the futility result nor the Fast Track designation the company announced. On 23 September 2026 an independent monitoring board found the interim result below the threshold to continue, and the company attributed part of that to a significant amount of missing data — the most consequential setback yet for the joint-health case.
How It Works
PPS works by coating and protecting damaged tissue surfaces, reducing inflammation, and potentially supporting cartilage repair. In the bladder, it helps restore the protective lining. In joints, it may support the health of cartilage and synovial fluid.
The FDA label states plainly that the mechanism by which PPS achieves its effects in patients is unknown. The leading hypothesis is that this glycosaminoglycan-like compound (molecular weight 4,000 to 6,000 daltons) adheres to the bladder lining and buffers it against irritating substances in urine; similar binding to damaged cartilage is proposed for joints. In animal models it inhibits complement activation, reduces inflammatory mediator release, and has anti-coagulant properties. In cartilage, it stimulates proteoglycan synthesis, inhibits metalloproteinases, and supports chondrocyte function.
Evidence Snapshot
Human Clinical Evidence
Moderate-to-strong but mixed for interstitial cystitis: in the pivotal trial behind the label, 38% on PPS versus 18% on placebo had more than 50% improvement in bladder pain, and meta-analyses favor PPS, but the largest modern randomized trial found no benefit over placebo. Limited for joint applications: small positive pilot and Phase 2 biomarker trials, then a Phase 3 knee-OA trial that met its futility criterion in September 2026.
Animal / Preclinical
Moderate. Extensive veterinary use, but the veterinary randomized trials are small and mixed — no difference in lameness or radiographic progression in dogs after cruciate surgery, no benefit from intravesical PPS in obstructed cats, and inconsistent outcomes in horse osteoarthritis — and the two equine studies tested PPS only inside combinations, so neither isolates its contribution. A 2026 placebo-controlled trial in twenty dogs with naturally occurring osteoarthritis points the other way, reporting improvements in pain, joint function and cartilage volume out to six months on weekly subcutaneous dosing.
Mechanistic Rationale
Strong. Well-characterized glycosaminoglycan pharmacology.
Research Gaps & Open Questions
What the current literature has not yet settled about Pentosan Polysulfate:
- 01Mechanism of pigmentary maculopathy — the biological basis for the unique RPE-level changes seen with long-term PPS use is not fully characterized; understanding the mechanism would clarify whether risk plateaus or continues to accumulate with exposure.
- 02Reversibility of maculopathy — current evidence suggests the retinal changes can progress even after PPS discontinuation, but the long-term natural history after stopping is still being mapped.
- 03Dose-response and threshold for ocular risk — meta-analytic work has begun to characterize cumulative-dose relationships; precise risk thresholds and individual susceptibility factors are not fully resolved.
- 04Comparative efficacy in IC — PPS is the only FDA-approved oral therapy for IC, but comparative-effectiveness data versus newer modalities (intravesical instillations, neuromodulation, behavioral approaches) is limited.
- 05Joint/cartilage applications in humans — most joint data is veterinary or small human studies; the first large Phase 3 randomized trial of injectable PPS for knee osteoarthritis (PARA_OA_012) met its futility criterion at interim analysis in September 2026, and whether missing data obscured a real effect will not be known until the full dataset is reviewed.
- 06Gut toxicity — case series and cohort work link PPS to colitis, colonic dysplasia, and severe polyposis, and a 2026 case series now argues for colonoscopy screening in exposed patients even without gastrointestinal symptoms, on the strength of how often the polyposis it found was asymptomatic. Causality and incidence remain unresolved, and no guideline has adopted the recommendation.
- 07Who is most susceptible — besides cumulative dose, a 2026 screening study of 187 patients linked higher maculopathy risk to female sex, older age, higher dose per body weight, lower body weight, and inflammatory bowel or irritable bowel syndrome; whether weight-based dosing would reduce risk is untested.
- 08Subcutaneous injectable use in humans — research-chemical and off-label injectable PPS protocols in humans lack a controlled evidence base, and case reports of retinal toxicity from injectable use suggest the maculopathy concern is not limited to oral exposure.
Forms & Administration
Available orally as Elmiron, the only FDA-approved human form, which is indicated for interstitial cystitis. Injectable pentosan polysulfate for people is investigational (Paradigm's Zilosul) or compounded; the licensed injectables are veterinary — Zycosan for horses in the US, Cartrophen Vet for dogs abroad. Injecting is not the lower-risk route: maculopathy has been reported after low cumulative subcutaneous doses, and the Elmiron label warns that a similar injected product was associated with delayed immunoallergic thrombocytopenia. All injectable products should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
The FDA-approved oral dose for interstitial cystitis is 100 mg three times daily (300 mg/day total) on an empty stomach (1 hour before or 2 hours after meals). Veterinary injectable regimens are typically 3 mg/kg once weekly for four doses — intramuscular for Zycosan, the FDA-approved horse product, and subcutaneous in canine trials. Human knee-osteoarthritis trials used 2 mg/kg subcutaneously twice weekly for 6 weeks in the Phase 3 program, and 3 mg/kg intramuscularly weekly for 4 weeks in an older Australian pilot. Off-label injectable use in humans for joint applications has no established dose; protocols circulating in the longevity community are extrapolations rather than evidence-based regimens.
Frequency
For IC: three times daily, every day, with periodic clinical and (now) ophthalmologic reassessment. The drug is not cycled in the conventional sense; treatment continues as long as benefit outweighs risk.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
There is no formal cycle. In practice, the maculopathy literature has shifted clinical thinking toward periodic reassessment of whether continued long-term use is justified, particularly past several years of cumulative exposure.
Protocol Notes
PPS clinical effect for IC is slow to emerge — many patients require 3–6 months of treatment before deciding whether the drug is helping. Capsules are taken with water at least 1 hour before or 2 hours after meals, as in the trials, though the label states the effect of food on absorption is not known. Only about 6% of an oral dose reaches the bloodstream. The label tells prescribers to reassess at 3 months, allow another 3 months if there has been no improvement and side effects are tolerable, and notes that the value of continuing past 6 months without pain improvement is unknown. The most important contemporary management consideration is ophthalmologic surveillance, and the label is more specific than it is often summarized. It asks for a detailed ophthalmologic history in every patient before starting, and genetic testing where there is a family history of hereditary pattern dystrophy. A comprehensive baseline examination before therapy is recommended for patients who already have an ophthalmologic condition; for everyone else, a baseline examination including OCT and autofluorescence imaging is suggested within six months of starting, with periodic examinations after that. Concern rises with cumulative dose and duration of use. At 300 mg/day a patient accumulates roughly 110 g a year. A 2025 meta-analysis put maculopathy risk at about 1.65 times that of unexposed people at cumulative doses of 1–500 g, rising to 7.4 times at 2,000 g or more. The 21-year FAERS pharmacovigilance analysis published in Frontiers in Medicine, with a 2025 year of record and a PubMed entry in early 2026, underscored that maculopathy adverse events have a long latency (median ~4.7 years) and that female patients show stronger associations.
PPS is FDA-approved for interstitial cystitis. Off-label use for joint health, cartilage support, or longevity is not supported by approved labeling and carries the same maculopathy and bleeding-risk concerns that apply to its approved use.
Timeline of Effects
Onset
For interstitial cystitis symptoms, perceptible benefit typically requires several months — published trial data and clinical experience generally describe 3–6 months as the response window. For joint applications (where evidence is weaker), anecdotal reports describe slower onset over weeks to months, but controlled human data is limited.
Peak Effect
Most people who are going to respond do so within 6 months: in the large open-label study behind the label, 29% of enrolled patients had improved pain scores by 3 months, another 5% by 6 months, and fewer than 1.5% first improved after that. There is no clearly defined peak for joint applications.
After Discontinuation
Symptomatic benefit in IC tends to fade gradually over weeks to months following discontinuation, though some patients describe sustained improvement after extended treatment. Critically, the maculopathy associated with long-term PPS use can progress even after the drug is stopped — this is not a typical reversible drug toxicity, and ongoing ophthalmologic follow-up is appropriate even after discontinuation.
Common Questions
Is Pentosan Polysulfate FDA-approved?
Yes, as Elmiron for interstitial cystitis. Off-label use for joint health should be discussed with a clinician.
Are there safety concerns?
Long-term use of oral PPS (Elmiron) has been associated with a unique pigmentary maculopathy affecting vision. This is an important consideration for long-term use.
Is pentosan polysulfate actually a peptide?
No. PPS is a semi-synthetic polysulfated polysaccharide derived from beechwood xylan, not a peptide. It is grouped with peptide and tissue-repair discussions because of overlapping use cases (joint, cartilage, soft tissue) and shared glycosaminoglycan vocabulary, not because of chemical relatedness.
Why do the published risk numbers vary so much?
Because the studies are not measuring the same thing. A 2026 clinical-pharmacology review argues that the divergence mostly reflects differences in who was studied, how much drug they had taken, and how hard anyone looked for retinal change — not genuinely contradictory evidence. Screening cohorts that image every participant find high rates; claims databases that rely on a recorded diagnosis find low ones. Cumulative dose differs by an order of magnitude between studies, which alone moves the risk estimate severalfold. And the endpoint matters: a 2026 matched analysis of 6,418 interstitial cystitis patients found no difference in visual acuity between PPS users and non-users, but acuity is a poor detector here — the original Emory case series described maculopathy in patients whose acuity was largely intact. The reasonable summary is that the maculopathy is real and exposure-related, that absolute risk is genuinely contested, and that the same review cautions against treating a cumulative-dose number as a mandatory stopping rule.
Do I need a colonoscopy if I take Elmiron?
No guideline says so, but the question is now live. A 2026 retrospective case series of patients with PPS maculopathy found colonic polyposis often enough, and often enough without symptoms, that its authors argued for colonoscopy screening in exposed patients regardless of gastrointestinal complaints. A separate cohort found about 3.3 times the odds of inflammatory bowel disease in PPS users. There is one encouraging asymmetry with the eye: where the maculopathy keeps progressing after the drug is stopped, the colopathy has been reported to improve clinically and histologically after cessation. This is a conversation to have with the prescribing clinician rather than a settled recommendation.
How common is Elmiron eye damage?
It depends on dose and on how carefully people are screened. An Emory screening study estimated that between 3.8% and 24.5% of its PPS users had signs of toxicity, and a prospective cohort found 15%. A large US claims study put the risk at 2.6 times that of amitriptyline users overall, rising to 9.5 times with more than three years of use, and calculated one extra case for every 250 people treated during the first four years. A nationwide Korean study of 103,553 users against 205,792 non-users found a much smaller hazard ratio of 1.34, at a mean cumulative dose of only 37 grams. Risk climbs steeply with that dose: a 2025 meta-analysis found about 1.65 times the risk at 1 to 500 grams and 7.4 times at 2,000 grams or more, and the Emory screening cohort put the heaviest-exposure group, at 2,000 grams or more, at odds of 39.8 against the lightest.
Did injectable pentosan (Zilosul) work for knee arthritis?
Not in its pivotal test. On 23 September 2026 Paradigm Biopharmaceuticals announced that its Phase 3 trial, PARA_OA_012, fell below the pre-specified threshold to continue at a planned interim analysis conducted after about half the participants reached the day-112 endpoint. The company said operational problems left a significant amount of missing data and that it was reviewing the full dataset. Earlier signals had been more encouraging — a 2005 pilot trial in 114 patients and a 2026 Phase 2 study showing sustained falls in a cartilage-breakdown marker in joint fluid — but pentosan polysulfate is not approved for arthritis in people anywhere.
Is pentosan approved for dogs and horses?
In the US, the FDA approved Zycosan, an injectable pentosan polysulfate, for control of osteoarthritis signs in horses in December 2022, dosed at 3 mg/kg intramuscularly once weekly for four weeks. Cartrophen Vet for dogs is registered in Australia, New Zealand, Canada, the UK, and much of Europe, but not in the US. Veterinary approval says nothing about safety or efficacy for people: the human product is approved only for interstitial cystitis.
How long does PPS take to work for interstitial cystitis?
PPS is slow to act. Published trial data and clinical experience generally describe 3–6 months as the response window for IC symptoms, and the FDA label advises reassessing at 3 months and reconsidering at 6 months if pain has not improved. In the large open-label study behind the label, fewer than 1.5% of patients first noticed relief after 6 months. Capsules are taken with water 1 hour before or 2 hours after meals.
Does the maculopathy reverse if I stop the drug?
No. A four-year prospective study that followed patients after they stopped found continued progression of both structural and functional deficits — a loss of about five ETDRS letters over the four years, and new complete retinal pigment epithelium and outer retinal atrophy in roughly a third of the eyes still at risk. This is not a typical reversible drug toxicity, and the FDA label says plainly that follow-up examinations should continue because retinal and vision changes may progress after treatment stops. Case reports published in 2026 describe maculopathy that only became clinically apparent years after cessation. The 21-year FAERS analysis adds that the median time to onset is around 4.7 years, so neither onset nor progression tracks closely with when someone is actually taking the drug.
Who Pentosan Polysulfate Is NOT For
- •Pre-existing retinal or macular disease — the label asks for a detailed ophthalmologic history in every patient before starting, and a comprehensive baseline examination before therapy specifically for anyone who already has an ophthalmologic condition. It also calls for genetic testing where there is a family history of hereditary pattern dystrophy; at least one reported maculopathy case was homozygous for previously identified risk alleles.
- •Known hypersensitivity to PPS, structurally related compounds, or capsule ingredients — the only formal contraindication on the US label. A history of heparin-induced thrombocytopenia warrants caution: PPS itself has been reported to cause thrombocytopenia with thrombosis, and the label notes that a similar product given by injection was linked to delayed immunoallergic thrombocytopenia.
- •Conditions that raise bleeding risk — the label says patients with aneurysms, thrombocytopenia, hemophilia, gastrointestinal ulcerations, polyps, or diverticula should be carefully evaluated before starting, because PPS is a weak anticoagulant (about one-fifteenth the activity of heparin).
- •Inflammatory bowel disease or a history of colon polyps — case series link long-term PPS to colitis, colonic dysplasia, and severe adenomatous polyposis, some requiring colectomy, and one study found 3.3-fold higher odds of an IBD diagnosis among PPS users with interstitial cystitis.
- •Liver impairment — PPS has not been studied in hepatic insufficiency, the liver contributes to its elimination, and mild liver-enzyme elevations occurred in 1.2% of trial patients.
- •Active bleeding or significant bleeding diatheses — PPS has anticoagulant activity that can compound bleeding risk.
- •Concurrent high-dose anticoagulation or antiplatelet therapy without specialist coordination — additive bleeding risk.
- •Recent or planned surgery or other invasive procedures — the label says these patients should be evaluated for hemorrhage; whether and when to pause PPS is a decision for the surgeon and prescriber.
- •Pregnancy — limited human data; risk-benefit decision should involve a specialist familiar with both IC management and obstetric medicine.
- •Pre-existing macular disease or strong family history of vision loss — the pigmentary maculopathy risk is more concerning in patients whose baseline retinal status is already compromised.
- •Children and teenagers under 16 — the FDA label states that safety and effectiveness below age 16 have not been established.
Drug & Supplement Interactions
PPS's most clinically important interactions are pharmacodynamic and relate to bleeding risk, given its heparin-like anticoagulant activity. The most significant concern is co-administration with anticoagulants (warfarin, direct oral anticoagulants, low-molecular-weight heparins) and antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor). Additive effects on coagulation and platelet function may meaningfully increase bleeding risk, particularly in patients undergoing procedures or with other bleeding risk factors. NSAIDs, especially at high doses or in chronic use, can also contribute to additive GI bleeding risk via independent mechanisms. Only about 6% of an oral dose is absorbed; most passes unchanged in the stool, and the absorbed fraction is broken down by partial desulfation in the liver and spleen and depolymerization in the kidney, so classic CYP-based interactions are not a major feature. In a study described in the label, PPS 100 mg every 8 hours for 7 days did not change warfarin levels or INR — the concern with anticoagulants is additive bleeding, not a pharmacokinetic interaction. The drug does interact pharmacodynamically with the urothelial environment, and concurrent intravesical therapies for IC (DMSO, lidocaine, hyaluronic acid, others) are a matter of clinical sequencing rather than chemical interaction. Cumulative PPS exposure is the dominant driver of the retinal toxicity, but co-administered drugs are no longer entirely out of the picture. A 2026 study of 336 interstitial cystitis patients found that those with pigmentary maculopathy were considerably more likely to have had concurrent exposure to PPS plus amitriptyline or nortriptyline (75% versus 34.9%) or to PPS plus cyclosporine (37.5% versus 1.6%) — both of them standard interstitial cystitis co-medications. The same study found that PPS exposure, and not interstitial cystitis itself, was what tracked with maculopathy. Whether the tricyclics and cyclosporine contribute to the toxicity or simply mark heavier and longer treatment is unresolved. Patients on chronic PPS taking other retinotoxic medications (chloroquine, hydroxychloroquine, tamoxifen) should also be evaluated and monitored as appropriate to each agent.
Safety Profile
Common Side Effects
Cautions
- • FDA warning about pigmentary maculopathy with long-term oral use
- • Regular eye exams recommended for long-term users
- • May increase bleeding risk
What We Don't Know
The mechanism of retinal toxicity is not fully understood. A 21-year pharmacovigilance analysis (11,471 reports, 2004-2025) found 68.1% of PPS adverse event reports were classified as serious, with a median time-to-onset of 1,715 days (about 4.7 years) among the 297 reports that had usable timing data. Eye disorders showed the strongest signal, and depression/anxiety emerged as significant non-ocular concerns. Females showed prominent maculopathy associations. Subcutaneous injections, not just oral use, have also been linked to retinal toxicity: a 2026 case series described three arthritis patients with classic PPS maculopathy after cumulative injected doses of only 45.5 to 96 g over 7 to 10 years, possibly because injected PPS has roughly ten-fold higher bioavailability. Separately, PPS has been linked to a drug-associated colopathy spanning colitis, dysplasia, and polyposis.
Legal Status
United States
FDA-approved as Elmiron for the relief of bladder pain or discomfort associated with interstitial cystitis (1996). Prescription-only. On June 16, 2020 the FDA approved labeling that added a Retinal Pigmentary Changes warning. It suggests retinal imaging (OCT and autofluorescence) within six months of starting and periodically thereafter, and says follow-up should continue after stopping because changes can still progress. Off-label use in humans for joint or cartilage applications is not approved, and Drugs@FDA lists only one human PPS product, Janssen's Elmiron, with no approved generics. Paradigm Biopharmaceuticals' injectable PPS (Zilosul) holds FDA Fast Track designation for knee osteoarthritis, but its Phase 3 trial met its futility criterion in September 2026.
International
In the EU, Elmiron was centrally authorised on 2 June 2017 (holder bene-Arzneimittel, Munich), but only for bladder pain syndrome characterised by glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency, and frequency — a narrower indication than the US one. Veterinary formulations (Cartrophen and others) are widely available for canine and equine joint disease in countries including Australia, Canada, the UK, and many European markets, with country-specific regulatory status. Maculopathy concerns and labeling updates have been adopted by major regulators internationally.
Sports & Competition
PPS is not specifically listed on the WADA Prohibited List. Its anticoagulant activity could theoretically draw scrutiny in some bleeding-related contexts, but it is not a metabolic or anabolic enhancer. Because PPS is an approved human medicine, it also falls outside WADA's S0 catch-all for non-approved substances, so a Therapeutic Use Exemption is not normally required. Athletes should still confirm with their national anti-doping organization.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
The eye risk is settled science.
Reality
That the maculopathy exists and tracks with cumulative exposure is settled. How large the risk is, is not. Published estimates range from a hazard ratio of 1.34 in a Korean national cohort of more than 300,000 people to 24.5% prevalence in an intensively imaged screening cohort, and a 2026 matched study of 6,418 patients found no visual-acuity difference at all. A 2026 clinical-pharmacology review attributes most of that spread to differences in population, cumulative exposure and how carefully anyone looked, rather than to contradictory findings. Meanwhile a 2025 review in Progress in Retinal and Eye Research concludes that the mechanism remains unclear while the evidence for causality keeps strengthening. Both halves are true at once, and anyone quoting a single percentage is quoting one study.
Myth
Low doses or injections avoid the eye risk.
Reality
Risk rises with cumulative dose, but no safe threshold has been established. The FDA label notes that although most cases appeared after three years of use or longer, some were seen with shorter exposure. And the route does not protect you: a 2026 case series described three arthritis patients who developed classic PPS maculopathy after cumulative subcutaneous doses of only 45.5 to 96 grams, far below typical oral exposures, possibly because injected PPS is absorbed about ten times more efficiently.
Myth
The eyes are the only organ at risk with long-term Elmiron.
Reality
Researchers have described a separate PPS-associated colopathy in long-term users — colitis, colonic dysplasia, and severe adenomatous polyposis, in some cases severe enough to require colectomy. One study found 3.3-fold higher odds of an inflammatory bowel disease diagnosis among PPS users, and a 2026 screening study found that having IBD or IBS was itself associated with higher odds of maculopathy.
Myth
Pentosan polysulfate is a peptide.
Reality
PPS is a semi-synthetic polysulfated polysaccharide derived from beechwood xylan — not a peptide. It is grouped with peptide and tissue-repair discussions because of overlapping use cases and shared glycosaminoglycan vocabulary, not chemical relatedness.
Myth
Elmiron is essentially a benign long-term medication.
Reality
While generally tolerated for many patients in the short term, long-term oral PPS has been associated with a unique pigmentary maculopathy that can cause irreversible vision changes. The 2018+ literature substantially changed the risk-benefit conversation, and ophthalmologic surveillance is now part of appropriate management.
Myth
Subcutaneous PPS for joint health is supported by the same evidence as oral PPS for interstitial cystitis.
Reality
Oral PPS for IC has decades of randomized trial data and FDA approval. Subcutaneous PPS for human joint applications does not have an equivalent evidence base; most joint data is veterinary. Reports of retinal toxicity from injectable use suggest the maculopathy concern may apply to injected as well as oral exposure.
Myth
Maculopathy from PPS is fully reversible once you stop the drug.
Reality
Current evidence indicates that PPS-associated maculopathy can progress even after discontinuation. This is not a typical reversible drug toxicity, which is part of why baseline and serial ophthalmologic monitoring during treatment matters so much.
Myth
PPS is safe to combine with other anticoagulants because the dose is small.
Reality
PPS has measurable heparin-like anticoagulant activity, and additive effects with warfarin, direct oral anticoagulants, antiplatelet drugs, or high-dose NSAIDs can meaningfully increase bleeding risk. Patients on these combinations need active medical management, not casual coadministration.
Published Research
51 studiesPentosan polysulfate sodium and retinal safety: reconciling conflicting evidence and defining a pragmatic clinical pharmacology framework.
Argues that the wildly different published risk estimates reflect differences in population selection, cumulative exposure range and how hard anyone looked for retinal change — not contradictory evidence — and cautions against treating a cumulative-dose threshold as a mandatory stopping rule.
Retrospective study of visual acuity changes in patients with interstitial cystitis receiving pentosan polysulfate sodium.
The main counterweight in the safety literature: a matched analysis of 6,418 interstitial cystitis patients found no evidence that PPS exposure affected visual-acuity progression. Acuity is an insensitive endpoint here — the original case series found maculopathy in eyes whose acuity was largely intact — and the study is industry-linked.
Risk factors for pentosan polysulfate maculopathy.
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series.
Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis.
Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia.
Post-marketing safety of pentosan polysulfate sodium: a 21-year pharmacovigilance analysis of the FAERS database.
Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial.
Pentosan Polysulfate Maculopathy Following Subcutaneous Injections for Arthritis.
Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies.
Separates the drug from the disease — PPS exposure, not interstitial cystitis itself, tracked with pigmentary maculopathy across 336 patients — and raises the first co-medication signal, with amitriptyline, nortriptyline and cyclosporine all more common in the affected group.
Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality.
The standing review of the causality question: the pathogenic mechanism is still unclear, but the authors judge that the accumulated evidence now supports a causal relationship rather than an association.
Colopathy associated with pentosan polysulfate use.
Risk and Dose-Response Relationship for Pentosan Polysulfate Sodium Maculopathy: A Systematic Review and Meta-Analysis
Pentosan polysulfate sodium maculopathy: Final analysis of a prospective cohort, updated review, and association with inflammatory bowel disease.
The prospective cohort behind the 15% prevalence figure — 154 subjects, with multimodal imaging characteristics and the inflammatory bowel disease association described in full.
Pentosan Polysulfate Maculopathy: Final Outcomes from a 4-Year Prospective Study of Disease Progression after Drug Cessation.
The proper source for the claim repeated everywhere about this drug — that the retinal damage keeps advancing after you stop. Four years of prospective follow-up after cessation found a loss of about five ETDRS letters and new complete retinal pigment epithelium and outer retinal atrophy in roughly a third of the eyes still at risk.
Association between Pentosan Polysulfate and Subsequent Maculopathy: Insights from a Nationwide Population-Based Study in Korea.
The largest population study of the question — 103,553 users against 205,792 non-users — and the lowest risk estimate, a hazard ratio of 1.34, at a mean cumulative dose of only 37 grams. Read alongside the dose-response data, it reinforces exposure rather than contradicting the risk.
Open-label, single-center, clinical study evaluating the safety, tolerability and clinical effects of pentosan polysulfate sodium in subjects with mucopolysaccharidosis I.
Efficacy of Pentosan Polysulfate Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome
Pentosan Polysulfate-Associated Dysplasia in Patients With Inflammatory Bowel Disease: A Case Series.
A post-trial follow-up study of pentosan polysulfate monotherapy on preventing recurrent urinary tract infection in women
[Protective properties of urothelium and possibilities of targeted pathogenetic therapy of chronic pelvic pain: sodium pentosan polysulfate]
Risk of maculopathy with pentosan polysulfate sodium use.
The large US claims analysis behind the most-quoted risk figures: a hazard ratio of 2.64 against amitriptyline users overall, 9.56 beyond three years of use, and one extra case for every 250 people treated over four years.
Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study
Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis
Pentosan Polysulfate Maculopathy: What Urologists Should Know in 2020
Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis
The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial
Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials
Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high-risk women following gynecological surgery
Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium.
Pearce and colleagues at Emory, Ophthalmology 2018 — the report that first described a distinctive pigmentary maculopathy in long-term PPS users and triggered the wave of investigation leading to the 2020 FDA label warning.
Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis
Efficacy of intravesical pentosan polysulfate sodium in cats with obstructive feline idiopathic cystitis
Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study
The modern counterweight to the 1997 meta-analysis: 368 patients, 24 weeks, and no significant separation from placebo on the primary endpoint — the single most important negative result in the oral PPS literature.
Treatment of experimentally induced osteoarthritis in horses using an intravenous combination of sodium pentosan polysulfate, N-acetyl glucosamine, and sodium hyaluronan
Effects of pentosan polysulfate in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled pilot study.
Effects of intra-articular sodium pentosan polysulfate and glucosamine on the cytology, total protein concentration and viscosity of synovial fluid in horses
Contemporary management of the painful bladder: a systematic review
The risk for cross-reactions after a cutaneous delayed-type hypersensitivity reaction to heparin preparations is independent of their molecular weight: a systematic review
The relationship among symptoms, sleep disturbances and quality of life in patients with interstitial cystitis
Evaluation of health-related quality of life in patients with painful bladder syndrome/interstitial cystitis and the impact of four treatments on it
Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction
Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium
Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement
Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial
Evaluation of pentosan polysulfate sodium in the postoperative recovery from cranial cruciate injury in dogs: a randomized, placebo-controlled clinical trial
Potassium sensitivity test (PST) as a measurement of treatment efficacy of painful bladder syndrome/interstitial cystitis: a prospective study with cyclosporine A and pentosan polysulfate sodium
Pentosan polysulfate: a review of its use in the relief of bladder pain or discomfort in interstitial cystitis
Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study
Efficacy of pentosan polysulfate in the treatment of interstitial cystitis: a meta-analysis
The 1997 pooled analysis that underpins the approval-era efficacy case, and the source of the number worth carrying into any conversation about PPS: roughly seven patients must be treated for one to report meaningful pain relief.
FDA approves first injectable pentosan polysulfate (Zycosan) for osteoarthritis in horses (December 20, 2022)
Elmiron — European Medicines Agency EPAR (centrally authorised 2 June 2017)
Quick Facts
- Class
- Polysaccharide
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Nov 2026
- Citations
- 51PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.